ReP USP - Resultado da busca

Artigo de periodico
Tumor glycolytic profiling through 18F-FDG PET/CT predicts immune checkpoint inhibitor efficacy in advanced NSCLC (2022)
Silva, Saulo Brito; Wanderley, Carlos Wagner Souza; Marin, José Flavio Gomes; Macedo, Mariana Petaccia de; Nascimento, Ellen Caroline Toledo do; Antonacio, Fernanda Fronzoni; Figueiredo, Caroline Sales; Cunha, Mateus Trinconi ; Cunha, Fernando de Queiroz ; Castro Junior, Gilberto de
Source: Therapeutic Advances in Medical Oncology. Unidades: FMRP, FM
Subjects: BIOMARCADORES, GLICOSE, IMUNOTERAPIA, NEOPLASIAS PULMONARES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SILVA, Saulo Brito et al. Tumor glycolytic profiling through 18F-FDG PET/CT predicts immune checkpoint inhibitor efficacy in advanced NSCLC. Therapeutic Advances in Medical Oncology, v. 14, p. 1-13, 2022Tradução . . Disponível em: https://doi.org/10.1177/17588359221138386. Acesso em: 02 nov. 2024.
APA
Silva, S. B., Wanderley, C. W. S., Marin, J. F. G., Macedo, M. P. de, Nascimento, E. C. T. do, Antonacio, F. F., et al. (2022). Tumor glycolytic profiling through 18F-FDG PET/CT predicts immune checkpoint inhibitor efficacy in advanced NSCLC. Therapeutic Advances in Medical Oncology, 14, 1-13. doi:10.1177/17588359221138386
NLM
Silva SB, Wanderley CWS, Marin JFG, Macedo MP de, Nascimento ECT do, Antonacio FF, Figueiredo CS, Cunha MT, Cunha F de Q, Castro Junior G de. Tumor glycolytic profiling through 18F-FDG PET/CT predicts immune checkpoint inhibitor efficacy in advanced NSCLC [Internet]. Therapeutic Advances in Medical Oncology. 2022 ; 14 1-13.[citado 2024 nov. 02 ] Available from: https://doi.org/10.1177/17588359221138386
Vancouver
Silva SB, Wanderley CWS, Marin JFG, Macedo MP de, Nascimento ECT do, Antonacio FF, Figueiredo CS, Cunha MT, Cunha F de Q, Castro Junior G de. Tumor glycolytic profiling through 18F-FDG PET/CT predicts immune checkpoint inhibitor efficacy in advanced NSCLC [Internet]. Therapeutic Advances in Medical Oncology. 2022 ; 14 1-13.[citado 2024 nov. 02 ] Available from: https://doi.org/10.1177/17588359221138386
Artigo de periodico
Gasdermin D inhibition prevents multiple organ dysfunction during sepsis by blocking NET formation (2021)
Silva, Camila Meirelles de Souza; Wanderley, Carlos Wagner Souza; Veras, Flávio Protásio ; Sônego, Fabiane; Nascimento, Daniele C.; Gonçalves, Augusto Velozo ; Martins, Timna Varela; Morelo, David Fernando Colon ; Borges, Vanessa F.; Brauer, Verônica Soares; Damasceno, Luis Eduardo Alves ; Silva, Katiussia P.; Toller-kawahisa, Juliana Escher; Batah, Sabrina Setembre ; Souza, Ana Letícia Júlio de; Monteiro, Valter Vinícius Silva; Oliveira, Antonio Edson Rocha; Donate, Paula Barbim; Zoppi, Daniel; Borges, Marcos de Carvalho ; Almeida, Fausto Bruno dos Reis ; Nakaya, Helder Takashi Imoto ; Fabro, Alexandre Todorovic ; Cunha, Thiago Mattar ; Alves Filho, José Carlos Farias ; Zamboni, Dario Simões ; Cunha, Fernando de Queiroz
Source: Blood. Unidades: FCFRP, FMRP, FCF
Subjects: FAGÓCITOS, GRANULÓCITOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SILVA, Camila Meirelles de Souza et al. Gasdermin D inhibition prevents multiple organ dysfunction during sepsis by blocking NET formation. Blood, v. 138, n. 25, p. 2702-2713, 2021Tradução . . Disponível em: https://doi.org/10.1182/blood.2021011525. Acesso em: 02 nov. 2024.
APA
Silva, C. M. de S., Wanderley, C. W. S., Veras, F. P., Sônego, F., Nascimento, D. C., Gonçalves, A. V., et al. (2021). Gasdermin D inhibition prevents multiple organ dysfunction during sepsis by blocking NET formation. Blood, 138( 25), 2702-2713. doi:10.1182/blood.2021011525
NLM
Silva CM de S, Wanderley CWS, Veras FP, Sônego F, Nascimento DC, Gonçalves AV, Martins TV, Morelo DFC, Borges VF, Brauer VS, Damasceno LEA, Silva KP, Toller-kawahisa JE, Batah SS, Souza ALJ de, Monteiro VVS, Oliveira AER, Donate PB, Zoppi D, Borges M de C, Almeida FB dos R, Nakaya HTI, Fabro AT, Cunha TM, Alves Filho JCF, Zamboni DS, Cunha F de Q. Gasdermin D inhibition prevents multiple organ dysfunction during sepsis by blocking NET formation [Internet]. Blood. 2021 ; 138( 25): 2702-2713.[citado 2024 nov. 02 ] Available from: https://doi.org/10.1182/blood.2021011525
Vancouver
Silva CM de S, Wanderley CWS, Veras FP, Sônego F, Nascimento DC, Gonçalves AV, Martins TV, Morelo DFC, Borges VF, Brauer VS, Damasceno LEA, Silva KP, Toller-kawahisa JE, Batah SS, Souza ALJ de, Monteiro VVS, Oliveira AER, Donate PB, Zoppi D, Borges M de C, Almeida FB dos R, Nakaya HTI, Fabro AT, Cunha TM, Alves Filho JCF, Zamboni DS, Cunha F de Q. Gasdermin D inhibition prevents multiple organ dysfunction during sepsis by blocking NET formation [Internet]. Blood. 2021 ; 138( 25): 2702-2713.[citado 2024 nov. 02 ] Available from: https://doi.org/10.1182/blood.2021011525
Artigo de periodico
SN-38, the active metabolite of irinotecan, inhibits the acute inflammatory response by targeting toll-like receptor 4 (2019)
Wong, Deysi Viviana T.; Ribeiro Filho, Helder Veras; Wanderley, Carlos Wagner Souza; Leite, Caio Abner Vitorino Gonçalves; Lima, Jonilson Berlink; Assef, Alexia Nathália Brígido; Cajado, Aurilene Gomes; Batista, Gabriela Loiola Ponte; González, Rafael Holanda; Silva, Karla Oliveira; Borges, Luis Philipi Carvalho; Alencar, Nylane Maria Nunes de; Wilke, Diego Veras; Cunha, Thiago Mattar ; Figueira, Ana Carolina Migliorini; Cunha, Fernando de Queiroz ; Lima Júnior, Roberto César P.
Source: Cancer Chemotherapy and Pharmacology. Unidade: FMRP
Subjects: INFLAMAÇÃO, FÁRMACOS, RECEPTORES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
WONG, Deysi Viviana T. et al. SN-38, the active metabolite of irinotecan, inhibits the acute inflammatory response by targeting toll-like receptor 4. Cancer Chemotherapy and Pharmacology, v. 84, n. 2, p. 287-298, 2019Tradução . . Disponível em: https://doi.org/10.1007/s00280-019-03844-z. Acesso em: 02 nov. 2024.
APA
Wong, D. V. T., Ribeiro Filho, H. V., Wanderley, C. W. S., Leite, C. A. V. G., Lima, J. B., Assef, A. N. B., et al. (2019). SN-38, the active metabolite of irinotecan, inhibits the acute inflammatory response by targeting toll-like receptor 4. Cancer Chemotherapy and Pharmacology, 84( 2), 287-298. doi:10.1007/s00280-019-03844-z
NLM
Wong DVT, Ribeiro Filho HV, Wanderley CWS, Leite CAVG, Lima JB, Assef ANB, Cajado AG, Batista GLP, González RH, Silva KO, Borges LPC, Alencar NMN de, Wilke DV, Cunha TM, Figueira ACM, Cunha F de Q, Lima Júnior RCP. SN-38, the active metabolite of irinotecan, inhibits the acute inflammatory response by targeting toll-like receptor 4 [Internet]. Cancer Chemotherapy and Pharmacology. 2019 ; 84( 2): 287-298.[citado 2024 nov. 02 ] Available from: https://doi.org/10.1007/s00280-019-03844-z
Vancouver
Wong DVT, Ribeiro Filho HV, Wanderley CWS, Leite CAVG, Lima JB, Assef ANB, Cajado AG, Batista GLP, González RH, Silva KO, Borges LPC, Alencar NMN de, Wilke DV, Cunha TM, Figueira ACM, Cunha F de Q, Lima Júnior RCP. SN-38, the active metabolite of irinotecan, inhibits the acute inflammatory response by targeting toll-like receptor 4 [Internet]. Cancer Chemotherapy and Pharmacology. 2019 ; 84( 2): 287-298.[citado 2024 nov. 02 ] Available from: https://doi.org/10.1007/s00280-019-03844-z

USP Schools

ReP

Filtros

Departament

Authors

USP affiliated authors

Subjects

Funding Agencies

Indexado em

Non normalized affiliation